Fisher Asset Management LLC Grows Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Fisher Asset Management LLC lifted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.3% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 18,155 shares of the biotechnology company’s stock after acquiring an additional 239 shares during the period. Fisher Asset Management LLC’s holdings in Sarepta Therapeutics were worth $2,267,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Innealta Capital LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth approximately $31,000. Huntington National Bank raised its holdings in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after buying an additional 175 shares during the last quarter. Nkcfo LLC acquired a new stake in shares of Sarepta Therapeutics during the second quarter worth $43,000. Riggs Asset Managment Co. Inc. grew its holdings in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 75 shares during the last quarter. Finally, UMB Bank n.a. increased its position in shares of Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 197 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

SRPT opened at $133.34 on Friday. The company has a market cap of $12.74 billion, a price-to-earnings ratio of 106.67 and a beta of 0.81. The firm’s fifty day simple moving average is $122.37 and its two-hundred day simple moving average is $131.48. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 52-week low of $78.67 and a 52-week high of $173.25.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday. HC Wainwright initiated coverage on shares of Sarepta Therapeutics in a report on Monday, November 25th. They issued a “sell” rating and a $80.00 price objective on the stock. Finally, Jefferies Financial Group began coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They set a “buy” rating and a $165.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.